vs
QWEST CORP（CTBB）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
QWEST CORP的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs -187.5%，领先200.2%），Revvity同比增速更快（5.9% vs -15.0%），Revvity自由现金流更多（$161.8M vs $160.0M），过去两年Revvity的营收复合增速更高（9.0% vs -8.6%）
奎斯特公司（以CenturyLink QC名义运营）是一家隶属于 lumen Technologies 的地区性贝尔运营公司。其前身为1911年成立的山地电话电报公司，先后更名为山地贝尔、美国西部通讯，2000年改为现名，业务整合了原Malheur Bell、西北贝尔、太平洋西北贝尔的运营资源。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CTBB vs RVTY — 直观对比
营收规模更大
CTBB
是对方的1.4倍
$772.1M
营收增速更快
RVTY
高出20.9%
-15.0%
净利率更高
RVTY
高出200.2%
-187.5%
自由现金流更多
RVTY
多$1.8M
$160.0M
两年增速更快
RVTY
近两年复合增速
-8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $-2.1B | $98.4M |
| 毛利率 | 67.9% | — |
| 营业利润率 | -183.2% | 14.5% |
| 净利率 | -187.5% | 12.7% |
| 营收同比 | -15.0% | 5.9% |
| 净利润同比 | -627.9% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTBBRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润CTBBRVTY
| Q4 25 | $-2.1B | $98.4M | ||
| Q3 25 | $176.0M | $46.7M | ||
| Q2 25 | $277.0M | $53.9M | ||
| Q1 25 | $284.0M | $42.2M | ||
| Q4 24 | $391.0M | $94.6M | ||
| Q3 24 | $365.0M | $94.4M | ||
| Q2 24 | $378.0M | $55.4M | ||
| Q1 24 | $353.0M | $26.0M |
毛利率CTBBRVTY
| Q4 25 | 67.9% | — | ||
| Q3 25 | 65.3% | 53.6% | ||
| Q2 25 | 68.2% | 54.5% | ||
| Q1 25 | 69.3% | 56.5% | ||
| Q4 24 | 71.2% | — | ||
| Q3 24 | 69.9% | 56.3% | ||
| Q2 24 | 71.6% | 55.7% | ||
| Q1 24 | 71.9% | 54.6% |
营业利润率CTBBRVTY
| Q4 25 | -183.2% | 14.5% | ||
| Q3 25 | 22.3% | 11.7% | ||
| Q2 25 | 33.1% | 12.6% | ||
| Q1 25 | 33.7% | 10.9% | ||
| Q4 24 | 40.7% | 16.3% | ||
| Q3 24 | 38.5% | 14.3% | ||
| Q2 24 | 40.3% | 12.4% | ||
| Q1 24 | 37.6% | 6.8% |
净利率CTBBRVTY
| Q4 25 | -187.5% | 12.7% | ||
| Q3 25 | 16.1% | 6.7% | ||
| Q2 25 | 24.3% | 7.5% | ||
| Q1 25 | 24.7% | 6.4% | ||
| Q4 24 | 30.2% | 13.0% | ||
| Q3 24 | 28.2% | 13.8% | ||
| Q2 24 | 28.7% | 8.0% | ||
| Q1 24 | 26.8% | 4.0% |
每股收益（稀释后）CTBBRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $39.0M | $919.9M |
| 总债务越低越好 | $1.7B | — |
| 股东权益账面价值 | $10.9B | $7.3B |
| 总资产 | $15.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资CTBBRVTY
| Q4 25 | $39.0M | $919.9M | ||
| Q3 25 | $36.0M | $931.4M | ||
| Q2 25 | $25.0M | $991.8M | ||
| Q1 25 | $40.0M | $1.1B | ||
| Q4 24 | $26.0M | $1.2B | ||
| Q3 24 | $22.0M | $1.2B | ||
| Q2 24 | $18.0M | $2.0B | ||
| Q1 24 | $14.0M | $1.7B |
总债务CTBBRVTY
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.9B | — |
股东权益CTBBRVTY
| Q4 25 | $10.9B | $7.3B | ||
| Q3 25 | $13.0B | $7.4B | ||
| Q2 25 | $12.8B | $7.6B | ||
| Q1 25 | $12.5B | $7.6B | ||
| Q4 24 | $12.2B | $7.7B | ||
| Q3 24 | $11.9B | $7.9B | ||
| Q2 24 | $11.5B | $7.9B | ||
| Q1 24 | $11.1B | $7.8B |
总资产CTBBRVTY
| Q4 25 | $15.8B | $12.2B | ||
| Q3 25 | $17.9B | $12.1B | ||
| Q2 25 | $17.8B | $12.4B | ||
| Q1 25 | $17.6B | $12.4B | ||
| Q4 24 | $17.4B | $12.4B | ||
| Q3 24 | $17.0B | $12.8B | ||
| Q2 24 | $16.6B | $13.4B | ||
| Q1 24 | $16.4B | $13.4B |
负债/权益比CTBBRVTY
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.17× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $402.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $160.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 14.5% | 21.0% |
| 资本支出强度资本支出/营收 | 22.0% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $938.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CTBBRVTY
| Q4 25 | $402.0M | $182.0M | ||
| Q3 25 | $427.0M | $138.5M | ||
| Q2 25 | $480.0M | $134.3M | ||
| Q1 25 | $453.0M | $128.2M | ||
| Q4 24 | $548.0M | $174.2M | ||
| Q3 24 | $627.0M | $147.9M | ||
| Q2 24 | $548.0M | $158.6M | ||
| Q1 24 | $471.0M | $147.6M |
自由现金流CTBBRVTY
| Q4 25 | $160.0M | $161.8M | ||
| Q3 25 | $252.0M | $120.0M | ||
| Q2 25 | $276.0M | $115.5M | ||
| Q1 25 | $250.0M | $112.2M | ||
| Q4 24 | $277.0M | $149.8M | ||
| Q3 24 | $396.0M | $125.6M | ||
| Q2 24 | $280.0M | $136.6M | ||
| Q1 24 | $194.0M | $129.7M |
自由现金流率CTBBRVTY
| Q4 25 | 14.5% | 21.0% | ||
| Q3 25 | 23.1% | 17.2% | ||
| Q2 25 | 24.2% | 16.0% | ||
| Q1 25 | 21.7% | 16.9% | ||
| Q4 24 | 21.4% | 20.5% | ||
| Q3 24 | 30.6% | 18.4% | ||
| Q2 24 | 21.3% | 19.7% | ||
| Q1 24 | 14.7% | 20.0% |
资本支出强度CTBBRVTY
| Q4 25 | 22.0% | 2.6% | ||
| Q3 25 | 16.0% | 2.6% | ||
| Q2 25 | 17.9% | 2.6% | ||
| Q1 25 | 17.6% | 2.4% | ||
| Q4 24 | 20.9% | 3.4% | ||
| Q3 24 | 17.9% | 3.3% | ||
| Q2 24 | 20.4% | 3.2% | ||
| Q1 24 | 21.0% | 2.7% |
现金转化率CTBBRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.43× | 2.97× | ||
| Q2 25 | 1.73× | 2.49× | ||
| Q1 25 | 1.60× | 3.03× | ||
| Q4 24 | 1.40× | 1.84× | ||
| Q3 24 | 1.72× | 1.57× | ||
| Q2 24 | 1.45× | 2.87× | ||
| Q1 24 | 1.33× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTBB
| Nonrelated Party | $665.0M | 60% |
| Other | $436.0M | 40% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
